Multiomic analysis of colorectal adenocarcinoma reveals a new subtype of myofibroblastic cancer-associated fibroblasts that express high levels of B7-H3 and have poor-prognosis value
We suggest that anti-B7-H3 immunotherapies might preferentially target cells from the microenvironment rather than tumor cells. This is particularly important for understanding the mode of action of the anti-B7-H3 antibody‒drug conjugate, which is currently being tested in clinical trials in several solid tumors.
Authors
- Maelle Picard (ORCID: https://orcid.org/0000-0001-9561-271X)
- Émilie Mamessier (ORCID: https://orcid.org/0000-0002-3516-0093)
- Bernadette de Rauglaudre (ORCID: https://orcid.org/0000-0003-2913-8129)
- Arnaud Guillé (ORCID: https://orcid.org/0000-0001-5747-562X)
- Lénaïg Mescam
- François Bertucci (ORCID: https://orcid.org/0000-0002-0157-0959)
- David Jérémie Birnbaum (ORCID: https://orcid.org/0000-0002-9026-3044)
- Nadiya Belfil
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Aix-Marseille Université (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Hôpital Nord (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut Paoli-Calmettes (FR)
- Hôpital de la Timone (FR)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013356
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00